



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

5/29/01

Adlene C. Mauer

PATENT

Attorney Docket No.: 17634-000340

Client Reference No.: E-029-00/0

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

TAO TAO et al.

Application No.: 09/459,062

Filed: December 10, 1999

For: CONSTRUCTION AND USE OF  
RECOMBINANT  
PARAINFLUENZA VIRUSES  
EXPRESSING A CHIMERIC  
GLYCOPROTEIN

Examiner: M. Mosher

Art Unit: 1648

**RESPONSE TO NOTICE TO COMPLY  
WITH SEQUENCE DISCLOSURE AND  
AMENDMENT**

#8  
w/ Seq. List  
+ Drug (sheet)  
6/9/01

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 28, 2001, Applicants submit the enclosed Paper Sequence Listing to be made of record in the above-referenced application, and a computer readable form (CRF) copy of the Sequence Listing. Pursuant to 37 CFR §1.821(f) and (g), it is believed that the content of the paper sequence listing and the computer readable sequence listing are the same. Further, the present submission of the Paper Sequence Listing and CRF Sequence Listing is not believed to constitute new matter.

Please amend the above-identified application as follows:

**IN THE SPECIFICATION:**

Please replace the paragraph beginning at page 29, line 32, with the following rewritten paragraph:

Figure 6 illustrates construction of the PIV3-PIV2 chimeric antigenomic cDNA pFLC.PIV32hc encoding the full-length PIV2 HN and F proteins. The cDNA fragment containing the full-length PIV2 F ORF flanked by the indicated restriction sites (A1) was amplified from PIV2/V94 vRNA using RT-PCR and a PIV2 F specific primer pair (1, 2 in Table

Adlene

TECH CENTER 1600/2900

JUN 08 2001

RECEIVED